Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine.
about
DNA methylation biomarkers: cancer and beyondMethylation analyses in liquid biopsyAsymmetric DNA methylation of CpG dyads is a feature of secondary DMRs associated with the Dlk1/Gtl2 imprinting cluster in mouseCXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomyBisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine.Bisulfite Conversion of DNA: Performance Comparison of Different Kits and Methylation Quantitation of Epigenetic Biomarkers that Have the Potential to Be Used in Non-Invasive Prenatal Testing.Aberrant methylation patterns in cancer: a clinical view.Methylation-assisted bisulfite sequencing to simultaneously map 5fC and 5caC on a genome-wide scale for DNA demethylation analysis.DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinomaMethylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer.Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.Current and Emerging Technologies for the Analysis of the Genome-Wide and Locus-Specific DNA Methylation Patterns.PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.Efficiency of methylated DNA immunoprecipitation bisulphite sequencing for whole-genome DNA methylation analysis.PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA.Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model.DNA Methylation Analysis of Free-Circulating DNA in Body Fluids.PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.DNA Methylation Analysis from Body Fluids.Quantitative comparison of DNA methylation assays for biomarker development and clinical applications.Comprehensive Evaluation of Commercial Bisulfite-Based DNA Methylation Kits and Development of an Alternative Protocol With Improved Conversion Performance.Comparison of whole-genome bisulfite sequencing library preparation strategies identifies sources of biases affecting DNA methylation data.Droplet digital PCR is an accurate method to assess methylation status on FFPE samples.Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR.METHimpute: imputation-guided construction of complete methylomes from WGBS data.
P2860
Q26996421-00F844D0-1173-42C3-B469-41B3AF164DBCQ28072859-C49E743C-06AE-41DB-A035-7F267FE9AF4FQ33823348-9664BFCE-8DB8-4657-B426-861D3ED84CC2Q34535488-C6F42086-178C-40B3-AD5F-DB809BFB3CC0Q34544461-58BF0B4A-FCD6-47EC-B32C-ABF097114AD3Q35681956-DE15792F-A063-406C-9170-87B92F26065CQ35738581-3EBF0643-CF75-4096-A09D-BC9A298606FCQ35750355-49F7ACFF-2C5C-4FEA-A8EE-9F92241D8EA0Q36047142-CEB939C3-2CFF-4BAF-AFC3-A4098919B019Q36370872-27063BAC-C264-4FC0-8272-C27EFD8D3777Q37623044-3D443825-C268-4CF5-AD56-2E0182EDC67DQ37689028-261B4D33-E0E4-4AA7-8A0D-D1BFE78B1DE1Q37708509-5025DBDE-52F1-4DCC-B2BA-532113EF026FQ38373884-746407A8-9C24-44DC-8590-C317495B8D08Q39003554-60B6E620-222D-4396-B34C-35502039A216Q39318240-C38DBC3D-F8D3-4DAB-97F1-3A6C2ABEB095Q39334962-5BC9D733-D900-4221-AD01-95331E7D0678Q39707073-05AB9833-F83A-4253-9B02-F323FC0DC39FQ40208391-D1365270-DF60-4212-8CE6-EED5573223BEQ47152528-C0208CBE-CC23-44F3-954F-8F5046298FFAQ47167930-020AA29B-37A4-484A-B733-F3100C15DC23Q47215343-4F8E198A-34F0-4ECD-BFDB-7F88B1D845CAQ47692611-5799A985-C63E-4FC5-B74C-4D74F252BB0CQ47789662-90F8E6D7-EC63-4DEC-A577-AEFABDFD5CE9Q49296229-090BB9DC-006B-4E45-B3CA-69418F415511Q49971205-9F97F9F8-BAB9-4608-A315-72CF30DBC004Q50054711-4C398B2D-6C10-427B-8794-C96CAEC88F7DQ50182604-E3225A79-A148-49B3-8AAB-06320C48AE63Q50620646-890B1756-1648-4907-8DE0-E28480350CFCQ52595267-83E7EE4D-B508-4315-A9CB-A1D5A0ACD4C6Q54966069-10F0A868-54C6-4C31-B259-BE18299D7AB7Q55114698-8EB52C18-BCA3-45D3-BBC3-77797CD0D8CFQ55265466-828D36E8-352C-4122-9609-4B234CB921DDQ55343750-AE20019B-8C81-4382-8992-6B6369D2CF3C
P2860
Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Performance evaluation of kits ...... ons, plasma, serum, and urine.
@ast
Performance evaluation of kits ...... ons, plasma, serum, and urine.
@en
type
label
Performance evaluation of kits ...... ons, plasma, serum, and urine.
@ast
Performance evaluation of kits ...... ons, plasma, serum, and urine.
@en
prefLabel
Performance evaluation of kits ...... ons, plasma, serum, and urine.
@ast
Performance evaluation of kits ...... ons, plasma, serum, and urine.
@en
P2093
P2860
P1433
P1476
Performance evaluation of kits ...... ions, plasma, serum, and urine
@en
P2093
Annette Leisse
Barbara Uhl
Dimo Dietrich
Emily Eva Holmes
Glen Kristiansen
Leif-Alexander Garbe
Maria Jung
Martina Mengdehl
Sebastian Meller
Verena Sailer
P2860
P304
P356
10.1371/JOURNAL.PONE.0093933
P407
P50
P577
2014-04-03T00:00:00Z